Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report

BACKGROUND: Chimeric antigen receptor T cell (CART) therapy has benefited many refractory lymphoma patients, but some patients experience poor effects. Previous studies have shown that programmed cell death protein-1 (PD-1) inhibitors can improve and prolong the therapeutic effect of CAR-T cell trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Zhi-Yun, Sun, Li, Wen, Shu-Peng, Song, Zheng-Rong, Xing, Lina, Wang, Ying, Li, Jian-Qiang, Zhang, Xue-Jun, Wang, Fu-Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026848/
https://www.ncbi.nlm.nih.gov/pubmed/33869619
http://dx.doi.org/10.12998/wjcc.v9.i10.2394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026848/
https://www.ncbi.nlm.nih.gov/pubmed/33869619
http://dx.doi.org/10.12998/wjcc.v9.i10.2394

Ejemplares similares